Hodgkin's Disease Clinical Trial
Official title:
Treatment With AMD3100 Added to a Mobilizing Regimen of G-CSF to Increase the Number of Peripheral Blood Stem Cells in Patients With Hodgkin's Disease
Participants with Hodgkin's Disease (HD) who have been treated with cyto-reductive chemotherapy, who are to undergo autologous stem cell transplantation, and who meet the inclusion/exclusion criteria are eligible to enter this efficacy, safety and pharmacokinetic (PK) study. The only changes to the standard of care is the addition of plerixafor to a granulocyte-colony stimulating factor (G-CSF) mobilization regimen on each day prior to apheresis. The purpose of this protocol is to determine the proportion of participants who reach a target number of CD34+ stem cells (≥5*10^6 cells/kg) after hematopoietic stem cell mobilization with G-CSF and plerixafor. Safety and PK parameters are also collected.
Participants with HD who have been treated with cyto-reductive chemotherapy, who are to
undergo autologous stem cell transplantation, and who meet the inclusion/exclusion criteria
are eligible to enter this study. The only changes to the standard of care is the addition
of plerixafor to a G-CSF mobilization regimen on the day prior to apheresis and the
collection of blood samples for pharmacokinetic (PK) analysis and pharmacodynamics (PD)
analysis by CD34+ fluorescence-activated cell sorting (FACS) analysis. Blood samples for PK
and CD34+ FACS analyses will be obtained prior to and after the first dose of plerixafor.
Participants will undergo mobilization with G-CSF (10 µg/kg daily) and will receive
plerixafor (240 µg/kg) on each day prior to apheresis. Participants will be apheresed for up
to 5 consecutive days in order to collect the target number of CD34+ stem cells, (≥5*10^6
cells/kg). After apheresis, all participants will be treated with high dose chemotherapy in
preparation for transplantation. Participants will be transplanted with cells obtained from
the G-CSF plus plerixafor mobilization regimen. In the event that a sufficient number of
cells for transplantation are not obtained from the collection, cells may be retained and
pooled for transplantation at the investigator's discretion.
The primary endpoint is the proportion of HD participants who collect ≥5*10^6 CD34+ cells/kg
with this mobilization regimen. The secondary endpoints include the safety of this
mobilization regimen, the proportion of participants who collect ≥2*10^6 CD34+ cells/kg, the
change in CD34+ cells circulating in the peripheral blood after a dose of plerixafor, and
the number of days of apheresis required to obtain ≥5*10^6 CD34+ cells/kg. In addition,
success of the transplantation will be evaluated by measuring the time to engraftment of
PMNs and PLTs. Participants will be followed for 12 months to assess transplant durability.
This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was
acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01665768 -
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
|
Phase 2 | |
Completed |
NCT01188798 -
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
|
Phase 3 | |
Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
Completed |
NCT00150462 -
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
|
Phase 1 | |
Completed |
NCT00606437 -
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
|
Phase 1 | |
Completed |
NCT02856646 -
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
|
||
Completed |
NCT01458288 -
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
|
Phase 2 | |
Completed |
NCT00990587 -
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
|
Phase 1 | |
Terminated |
NCT00594308 -
In-Vivo Activated T-Cell Depletion to Prevent GVHD
|
N/A | |
Completed |
NCT00469729 -
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
|
Phase 2/Phase 3 | |
Completed |
NCT00552825 -
Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children
|
N/A | |
Completed |
NCT00165438 -
Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy
|
N/A | |
Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A | |
Recruiting |
NCT02007811 -
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
|
Phase 1/Phase 2 | |
Completed |
NCT01221857 -
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00665314 -
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).
|
Phase 2 | |
Completed |
NCT00569842 -
Investigation of the Cylex® ImmuKnow® Assay
|
N/A | |
Completed |
NCT00256191 -
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00284804 -
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
|
Phase 2 | |
Completed |
NCT00144677 -
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
|
Phase 2 |